[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"NEXTGEN Bioscience\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":40},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100524139",false,"NCT06104839","Safety and Efficacy of Oral NXC-736 in Adult Participants With Moderate and Severe Alopecia Areata","A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 2a Study to Evaluate the Efficacy and Safety of NXC736 in Patients With Moderate and Severe Alopecia Areata","Inclusion Criteria:\n\n* Men or women between ≥19 and ≤65 years of age at the time of informed consent\n* Moderate and severe alopecia areata as assessed by a SALT score of 25% ≤ SALT \\\u003C 95% at Screening and Day 1\u002FBaseline\n* Current episode of hair loss for ≥6 months but \\\u003C8 years\n* Stable disease condition (no significant growth of hair) in the last 6 months as assessed by the Investigator\n* Willing to keep the same hair style and color (eg, hair products, process, and timing for hair appointments) for the duration of the study\n\nExclusion Criteria:\n\n* Participants with the following medical history confirmed during screening:\n\n  * ohter Types of alopecia other than alopecia areata (such as cicatricial\u002Fscarring alopecia \\[including central centrifugal cicatricial alopecia\\], traction alopecia, androgenic alopecia, telogen effluvium, etc.)\n* Active scalp inflammation, scalp infection, scalp psoriasis, or any other scalp condition that may interfere with the SALT assessment\n* Previous use of Janus kinase (JAK) inhibitor (oral or topical), including participation in clinical studies of JAK inhibitors","ALL","19 Years","65 Years",{"count":19,"type":20},73,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","The purpose of this study is to evaluate the safety and efficacy of NXC-736 monotherapy in participants with severe alopecia areata (AA).",[26],"Alopecia Areata","RECRUITING","2026-04-09",{"date":30,"type":31},"2026-04-13","ACTUAL",{"date":33,"type":31},"2024-09-01",{"date":35,"type":20},"2027-01-31",{"name":37,"class":38},"NEXTGEN Bioscience","INDUSTRY",2,""]